Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

被引：20

作者：

Loibl, Sibylle ^{[1
,2
]}

Huang, Chiun-Sheng ^{[3
,4
]}

Mano, Max S. ^{[5
]}

Mamounas, Eleftherios P. ^{[6
,7
]}

Geyer, Charles E. ^{[8
,9
]}

Untch, Michael ^{[10
,11
]}

Thery, Jean-Christophe ^{[12
]}

Schwaner, Ingo

Limentani, Steven ^{[13
]}

Loman, Niklas ^{[14
]}

Lubbe, Kristina ^{[15
]}

Chang, Jenny C. ^{[16
]}

Hatschek, Thomas ^{[17
]}

Tesarowski, David ^{[18
]}

Song, Chunyan ^{[18
]}

de Haas, Sanne Lysbet ^{[19
]}

Boulet, Thomas ^{[19
]}

Lambertini, Chiara ^{[19
]}

Wolmark, Norman ^{[8
,20
]}

机构：

[1] GBG, Neu Isenburg, Germany

[2] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ, Coll Med, Taipei, Taiwan

[5] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[6] NSABP Fdn, Orlando, FL USA

[7] Orlando Hlth Canc Inst, Orlando, FL USA

[8] NSABP Fdn, Pittsburgh, PA USA

[9] Univ Pittsburgh, Hillman Canc Ctr, Pittsburgh, PA USA

[10] AGO B, Berlin, Germany

[11] HELIOS Klinikum Berlin Buch, Berlin, Germany

[12] Ctr Henri Becquerel, Canc Ctr, Rouen, France

[13] Atrium Hlth, Charlotte, NC USA

[14] Skane Univ Hosp, Lund, Sweden

[15] Diakovere Henrietten Stift, Hannover, Germany

[16] Houston Methodist Canc Ctr, Houston, TX USA

[17] Karolinska Univ Hosp, Solna, Sweden

[18] Genentech Inc, San Francisco, CA 94080 USA

[19] F Hoffmann La Roche Ltd, Basel, Switzerland

[20] Univ Pittsburgh, Pittsburgh, PA USA

来源：

NPJ BREAST CANCER | 2022年 / 8卷 / 01期

关键词：

NEOADJUVANT CHEMOTHERAPY; HER2; PROGNOSIS;

D O I：

10.1038/s41523-022-00477-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 and trastuzumab in patients randomized in the phase III KATHERINE trial based on HER2-positive central testing of the pre-treatment core biopsy with HER2-negative central testing on their corresponding surgical specimen after neoadjuvant treatment. In the 70/845 (8.3%) patients with HER2-negative residual disease on retesting at surgery, there were 11 IDFS events in the 42 trastuzumab-treated patients (26.2%) and none in the 28 T-DM1-treated patients, suggesting that T-DM1 should not be withheld in this patient population.

引用

页数：6

共 50 条

[31] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
Mano, Max S.
FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
[32] Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
Recondo, Gonzalo, Jr.
de la Vega, Maximo
Galanternik, Fernando
Diaz-Canton, Enrique
Amadeo Leone, Bernardo
Leone, Jose Pablo
CANCER MANAGEMENT AND RESEARCH, 2016, 8 : 57 - 65
[33] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
Elsada, Ahmed
Doss, Sally
Robertson, Janet
Adam, E. Jane
LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
[34] Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
Cochereau, D.
Cottu, P.
ONCOLOGIE, 2015, 17 (04) : 194 - 196
[35] Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, Sara M.
Barry, William T.
Dang, Chau T.
Yardley, Denise A.
Moy, Beverly
Marcom, P. Kelly
Albain, Kathy S.
Rugo, Hope S.
Ellis, Matthew
Shapira, Iuliana
Wolff, Antonio C.
Carey, Lisa A.
Overmoyer, Beth A.
Partridge, Ann H.
Guo, Hao
Hudis, Clifford A.
Krop, Ian E.
Burstein, Harold J.
Winer, Eric P.
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (02): : 134 - 141
[36] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER
Guan, X.
Li, H. C.
Xia, Y.
Yang, Q.
Ma, A. X.
VALUE IN HEALTH, 2022, 25 (07) : S372 - S372
[37] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
Khattak, Monica N.
Chichura, Anna M.
Lang, Julie E.
ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (03) : 1423 - 1427
[38] Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial
Monica N. Khattak
Anna M. Chichura
Julie E. Lang
Annals of Surgical Oncology, 2024, 31 : 1423 - 1427
[39] Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer
Watanabe, Junichiro
Ito, Yoshinori
Saeki, Toshiaki
Masuda, Norikazu
Takano, Toshimi
Takao, Shintaro
Nakagami, Kazuhiko
Tsugawa, Koichiro
Nakagawa, Shintaro
Kanatani, Kazumitsu
Nakayama, Takahiro
IN VIVO, 2017, 31 (03): : 493 - 500
[40] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer (vol 80, pg 1723, 2020)
Lyseng-Williamson, Katherine A.
DRUGS, 2020, 80 (18) : 2001 - 2001

← 1 2 3 4 5 →